• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Wednesday 12/19/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

disease

  • 3:32 PM

    Expands Hospital Infection Control Product Line RIVER EDGE, NJ–NEPH, (Marketwired – Dec 27, 2016) – Nephros, Inc. (OTCQB: NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its HydraGuard™ 10″ UltraFilter.

    Read more
  • 4:27 PM

    SALT LAKE CITY, Nov. 29, 2016, GBSN, (GLOBE NEWSWIRE) — Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent 9,434,999 for the company’s amplification suppressor. This technology blocks detection of contaminants present in the environment that may result in a false positive result and potential misdiagnosis of a patient. The high sensitivity of molecular diagnostic testing makes it vulnerable to the influence of common environmental contaminants

    Read more
  • 2:33 PM

    Funds raised will support ongoing Phase II(b) clinical trial in Basal Cell Carcinoma Nevus Syndrome, an orphan cancer hereditary disease requiring life-long therapy with no approved pharmaceutical treatment License and Manufacturing Partner Mayne Pharma invests $2.8MM PR Newswire TAMPA, Fla. and SAN DIEGO, June 1, 2016 TAMPA, Fla. and SAN DIEGO, June 1, 2016 /PRNewswire/ — HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced

    Read more
  • 2:26 PM

    ORLANDO, Fla., April 27, 2016, IMUN, (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN) (the “Company”), a clinical-stage biotech company providing immunotherapy solutions for the treatment of autoimmune disease and cancer with a focus on emerging nations, today announced that Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has approved its patented Lodonal as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune system regulator. The receipt of NAFDAC’s approval will enable the

    Read more
  • 3:10 PM

    Jan 12, 2016, GTHP OTC Disclosure & News Service – Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today fourth quarter sales revenue for the LuViva® Advanced Cervical Scan was the highest since the launch of the product. LuViva product revenue was approximately $276,000 for the fourth quarter of 2015 versus approximately $183,000 for the same period of 2014, an increase of about 51%. Total sales for

    Read more
  • 4:35 PM

    http://www.publicwire.com SAN DIEGO, Calif., April 2, 2014 /PRNewswire via COMTEX/ — Mind Solutions, Inc. (OTCQB – VOIS), announces the receipt of a $1,000,000 funding commitment that will enable the Company to initiate its business model and further the development of their proprietary EEG/ BCI mobile headset. The funding commitment provided requires the Company to file an S-1 Registration Statement with the Securities Exchange Commission to become “Effective” prior to receiving funds. From there, the Company may draw down monthly tranches

    Read more
Public Wire Banner